Research
Hormonal
Sibutramine and Rimonabant, previously approved anti-obesity drugs, were withdrawn from the market due to serious adverse effects, specifically increased cardiovascular risk and psychiatric disorders, respectively.
Do not use Sibutramine or Rimonabant. They have been withdrawn from major markets (EU, USA, Canada) due to serious cardiovascular and psychiatric risks. Orlistat is the primary long-term pharmacological option available.
StrongRefutesHIGH confidence
Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects.
Why this rating
Based on regulatory actions and large-scale outcome trials (SCOUT) cited in the review.
Source
Anti-obesity drugs: a review about their effects and their safety
Giuseppe Derosa et al. · Expert Opinion on Drug Safety · 2012
DOI 10.1517/14740338.2012.675326
narrative_reviewCited 184×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Orlistat is the only currently available long-term pharmacological treatment for obesity in Europe because it offers a favorable safety profile regarding cardiovascular events and diabetic control, despite being less effective for weight reduction than withdrawn agents.Good
- GLP-1 receptor agonists (Exenatide and Liraglutide) are marketed drugs that suppress appetite and reduce body weight while improving glycemic control in diabetic patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →